Within 60 days of surgery, 555 patients (1781 grafts) underwent angiographic graft assessment, revealing the following graft patency rates: aspirin 325 mg daily, 93.5%; aspirin 325 mg 3 times daily, 92.3%; and aspi- rin 325 mg and dipyridamole 75 mg 3 times daily, 91.9%. Compared with the patency rate of placebo (85.2%), aspirin regimens significantly improved graft patency (P<0.05).16 In a subsequent report of 1-year graft patency assessed in 406 patients (1315 grafts), the graft occlusion rate was 15.8% in all of the aspirin groups combined compared with 22.6% for the placebo group (P=0.03). Thus, early postoperative aspirin administered for 1 year, regardless of dose, improved 60-day In addition to its graft patency benefits, several observa- tional studies have shown that aspirin use is associated with improved clinical outcomes after CABG. In 2002, Mangano evaluated the impact of aspirin administration within 48 hours after surgery. Among 5022 patients who survived the first 48 hours after surgery, aspirin (up to 650 mg daily) was administered to 59.7%. In their analysis, the authors reported that postoperative aspirin therapy within 48 hours of surgery was associated with a 68% reduction in the incidence of post- operative death (1.3% versus 4.0%, aspirin versus no aspirin; P<0.001). Aspirin was also associated with a 48% reduc- tion in the incidence of MI (2.8% versus 5.4%; P<0.001), a 50% reduction in the incidence of stroke (1.3% versus 2.6%; P=0.01), a 74% reduction in the incidence of renal failure (0.9% versus 3.4%; P<0.001), and a 62% reduction in the incidence of bowel infarction (0.3% versus 0.8%; P=0.01). 